Immutep Limited (NASDAQ:IMMP) Sees Large Growth in Short Interest

Immutep Limited (NASDAQ:IMMP) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,260,000 shares, a growth of 10.5% from the March 15th total of 1,140,000 shares. Based on an average daily trading volume, of 141,400 shares, the short-interest ratio is presently 8.9 days.

Hedge Funds Weigh In On Immutep

Several institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in Immutep in the 4th quarter valued at $29,000. GTS Securities LLC bought a new position in Immutep during the fourth quarter worth about $59,000. Meridian Wealth Management LLC boosted its holdings in Immutep by 3.6% in the 4th quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 11,250 shares during the period. BNP Paribas Financial Markets boosted its holdings in Immutep by 27.8% in the 4th quarter. BNP Paribas Financial Markets now owns 30,600 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 6,665 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Immutep by 15.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 81,928 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 10,813 shares in the last quarter. Institutional investors and hedge funds own 2.32% of the company’s stock.

Immutep Trading Down 7.2 %

Shares of IMMP opened at $2.31 on Tuesday. The firm’s 50-day simple moving average is $2.44 and its 200 day simple moving average is $2.21. Immutep has a 52 week low of $1.50 and a 52 week high of $3.90.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.